A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation

Biochemical and Biophysical Research Communications

Volumn 390, Issue 3, 2009, Pages 547-551

  Kato, Yukinari ^a,b   Jin, Genglin ^a   Kuan, Chien Tsun ^a   McLendon, Roger E ^a   Yan, Hai ^a   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b YAMAGATA UNIVERSITY   (Japan)

Author keywords

Astrocytoma; Glioblastoma; IDH1; Monoclonal antibody; Mutation; R132H

Indexed keywords

ARGININE; HISTIDINE; ISOCITRATE DEHYDROGENASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IMAB 1; MUTANT PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ARTICLE; ASTROCYTOMA; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; ARGININE; CELL LINE, TUMOR; GLIOMA; HISTIDINE; HUMANS; HYBRIDOMAS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; MICE; MICE, INBRED BALB C; MUTANT PROTEINS;

MUS; SENDAI VIRUS;

EID: 70449708940     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.10.001     Document Type: Article

References (18)

1. Kleihues P., Burger P.C., Collines V.P., Newcomb E.W., Ohagi H., and Cavenee W.K. Astrocytic tumors. Glioblastama (2000), International Agency for Research on Cancer Press, Lyons 29-39
2. DeAngelis L.M. Brain tumors. N. Engl. J. Med. 344 (2001) 114-123
3. Ohgaki H., and Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol. 170 (2007) 1445-1453
4. Ohgaki H., and Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. (2009)
5. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz Jr. L.A., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K., Shinjo S.M., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., and Kinzler K.W. An integrated genomic analysis of human glioblastoma multiforme. Science 321 (2008) 1807-1812
6. Balss J., Meyer J., Mueller W., Korshunov A., Hartmann C., and von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 116 (2008) 597-602
7. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K.W., Velculescu V.E., Vogelstein B., and Bigner D.D. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360 (2009) 765-773
8. Bleeker F.E., Lamba S., Leenstra S., Troost D., Hulsebos T., Vandertop W.P., Frattini M., Molinari F., Knowles M., Cerrato A., Rodolfo M., Scarpa A., Felicioni L., Buttitta F., Malatesta S., Marchetti A., and Bardelli A. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum. Mutat. 30 (2009) 7-11
9. Ichimura K., Pearson D.M., Kocialkowski S., Backlund L.M., Chan R., Jones D.T., and Collins V.P. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 11 (2009) 341-347
10. Watanabe T., Nobusawa S., Kleihues P., and Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am. J. Pathol. 174 (2009) 1149-1153
11. Sonoda Y., Kumabe T., Nakamura T., Saito R., Kanamori M., Yamashita Y., Suzuki H., and Tominaga T. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci. 100 (2009) 1996-1998
12. Sanson M., Marie Y., Paris S., Idbaih A., Laffaire J., Ducray F., El Hallani S., Boisselier B., Mokhtari K., Hoang-Xuan K., and Delattre J.Y. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J. Clin. Oncol. 27 (2009) 4150-4154
13. Nobusawa S., Watanabe T., Kleihues P., and Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin. Cancer Res. 15 (2009) 6002-6007
14. Zhao S., Lin Y., Xu W., Jiang W., Zha Z., Wang P., Yu W., Li Z., Gong L., Peng Y., Ding J., Lei Q., Guan K.L., and Xiong Y. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324 (2009) 261-265
15. Korshunov A., Meyer J., Capper D., Christians A., Remke M., Witt H., Pfister S., von Deimling A., and Hartmann C. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol. 118 (2009) 401-405
16. Mardis E.R., Ding L., Dooling D.J., Larson D.E., McLellan M.D., Chen K., Koboldt D.C., Fulton R.S., Delehaunty K.D., McGrath S.D., Fulton L.A., Locke D.P., Magrini V.J., Abbott R.M., Vickery T.L., Reed J.S., Robinson J.S., Wylie T., Smith S.M., Carmichael L., Eldred J.M., Harris C.C., Walker J., Peck J.B., Du F., Dukes A.F., Sanderson G.E., Brummett A.M., Clark E., McMichael J.F., Meyer R.J., Schindler J.K., Pohl C.S., Wallis J.W., Shi X., Lin L., Schmidt H., Tang Y., Haipek C., Wiechert M.E., Ivy J.V., Kalicki J., Elliott G., Ries R.E., Payton J.E., Westervelt P., Tomasson M.H., Watson M.A., Baty J., Heath S., Shannon W.D., Nagarajan R., Link D.C., Walter M.J., Graubert T.A., DiPersio J.F., Wilson R.K., and Ley T.J. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361 (2009) 1058-1066
17. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K., Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., and Velculescu V.E. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006) 268-274
18. Kang M.R., Kim M.S., Oh J.E., Kim Y.R., Song S.Y., Seo S.I., Lee J.Y., Yoo N.J., and Lee S.H. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int. J. Cancer 125 (2009) 353-355